Hidradenitis Suppurativa Pipeline Analysis Report 2024: Featuring 24+ Companies and 24+ Pipeline Drugs Including Vilobelimab (InflaRx), Secukinumab (Novartis), Avacopan (Chemo Centryx), Imsidolimab (AnaptysBio)
03 mai 2024 06h39 HE
|
Research and Markets
Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "Hidradenitis Suppurativa - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
Hidradenitis Suppurativa (HS) - Market Insight, Epidemiology And Market Forecast - 2032
25 avr. 2023 06h13 HE
|
Research and Markets
Dublin, April 25, 2023 (GLOBE NEWSWIRE) -- The "Hidradenitis Suppurativa (HS) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's...
Global Hidradenitis Suppurativa Market Forecast to 2030: Increasing Smoking Rates Drives Growth
13 avr. 2023 06h23 HE
|
Research and Markets
Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Global Hidradenitis Suppurativa Market: Analysis By Patients, By Drugs (Povorcitinib, Bimekizumab, Sonelokimab), By Region Size (The US, Europe, Rest...